Novo Nordisk presented post hoc analyses from the SELECT, STEP, ESSENCE, and OASIS clinical trials at the 2026 Scientific Sessions of the American Diabetes Association (ADA), highlighting data regarding the impact… read more.
Including blueberries, plums, blackberries, broad beans or cherries (washed down with green tea) in your five-a-day may be the best way to a healthier heart, new research suggests. A major research study involving scientists from the University of Reading, Harvard Medical… read more.
On the heels of updated cholesterol management guidance that recommends earlier screening and establishes target goals for LDL “bad” cholesterol based on an individual’s risk factors, a new Physicians Committee for Responsible… read more.
NICE (UK): Sotatercept, with other pulmonary arterial hypertension (PAH) treatments, can be used as an option to treat PAH in adults with World Health Organization functional class (WHO… read more.
Cytokinetics, Incorporated announced the first commercial European launch of Myqorzo (aficamten) in Germany for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy… read more.
Substantial variations in referrals for advanced heart failure therapies are apparent across the UK and Ireland, with no obvious link to geographical location or social deprivation to explain… read more.
Clinical Pharmacy Congress highlights High cholesterol is a key modifiable risk factor for cardiovascular disease, but many eligible patients are not receiving lipid-lowering therapy. A service evaluation by… read more.
Clocking up 90 to 120 weekly minutes of strength (resistance) training may be the sweet spot for lowering the risk of death, suggests a 30 year study, published… read more.
People born with heart defects experience their first acute heart attack at a significantly earlier age than others, according to a new national study from Lund University in… read more.
AstraZeneca’s Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to… read more.
Eating foods that contain common preservative food additives may increase the risks of high blood pressure and cardiovascular disease, according to research published in the European Heart Journal [1] today… read more.
BridgeBio Pharma, Inc. announced new data from the Phase III ATTRibute-CM study at Heart Failure 2026, organized by the Heart Failure Association of the European Society of Cardiology… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
